HER2+ Breast Cancer

Maria Vittoria Dieci, MD, discusses the prognostic value of tumor-infiltrating lymphocytes in patients with early HER2-positive breast cancer.

DCISionRT identified patients with HER2-positive breast cancer at higher risk of residual disease following breast-conserving surgery plus radiotherapy.

Dual HER2 blockade with trastuzumab plus pertuzumab may serve as an effective option for hormone receptor–positive, HER2-positive metastatic breast cancer.

Oleg Gluz, MD, highlights the feasibility of de-escalated neoadjuvant therapy plus trastuzumab and pertuzumab in patients with HR+/HER2+ breast cancer.

Breast cancer experts highlight early-phase and real-world studies of interest from the 2024 ESMO Congress.

Paolo Tarantino, MD, discusses advancements that may lead to more tailored treatment approaches in early-stage HER2+ breast cancer.

Neoadjuvant endocrine therapy or paclitaxel combined with trastuzumab and pertuzumab achieved notable survival benefits in HR-positive, HER2-positive early breast cancer.

Tumor infiltrating lymphocytes may have prognostic utility for OS outcomes with adjuvant chemotherapy and trastuzumab in early HER2-positive breast cancer.

Nancy U. Lin, MD, discusses the DESTINY-Breast12 trial of T-DXd in patients with HER2-positive metastatic breast cancer with or without brain metastases.

T-DXd showcased overall and intracranial activity in patients with HER2-positive metastatic breast cancer with stable and active brain metastases.

As more therapies emerge for HER2-positive, -low, or -negative breast cancer, pathologists highlight the need for more precise methods of evaluating HER2 expression.

HER2DX showed a strong association between ERBB2 mRNA score and survival outcomes in tumor samples from patients with advanced HER2-positive breast cancer.

Pyrotinib paired with metronomic vinorelbine was safe and displayed efficacy in HER2-positive advanced breast cancer after prior trastuzumab.

Sara M. Tolaney, MD, MPH, discusses standard-of-care frontline treatment approaches for patients with HER2-positive breast cancer.

Adjuvant trastuzumab plus concurrent chemotherapy led to inferior DFS outcomes when administered for 9 weeks vs 1 year in ERBB2-positive breast cancer.

Peter Forsyth, MD, discusses the evaluation of intrathecal dendritic cells for patients with TNBC/HER2-positive leptomeningeal disease.

Adrienne G. Waks, MD, discusses efforts to improve treatment outcomes for patients with HER2-positive breast cancer with residual disease.

Barbara Jane O’Brien, MD, discusses tucatinib plus trastuzumab and capecitabine for leptomeningeal metastases in HER2-positive breast cancer.

Rita Nanda, MD, discusses efforts to de-escalate adjuvant therapy for patients with select breast cancers who responded to neoadjuvant therapy.

Sara M. Tolaney, MD, MPH, discusses standard frontline treatment approaches for patients with HER2-positive breast cancer.

The EMA has validated a type II variation application for trastuzumab deruxtecan for select patients with HER2-low or -ultralow metastatic breast cancer.

Adrienne G. Waks, MD, discusses how neoadjuvant and adjuvant anthracycline- and taxane-based regimens compare with one another in HER2+ breast cancer.

Sara M. Tolaney, MD, MPH, discusses the use of ADCs in HER2-positive breast cancer and ongoing research in this patient population.

Sara M. Tolaney, MD, MPH discusses ongoing clinical trials investigating the addition of HER2-directed therapies to existing treatment regimens for HER2-positive breast cancer.

Sara M. Tolaney, MD, MPH, discusses the HER2-positive breast cancer treatment paradigm and how standard agents may be optimized to improve outcomes.

In case you missed any, below is a recap of every OncLive On Air episode that aired in July 2024.

Adrienne G. Waks, MD, discusses the potential for pCR-guided treatment and highlights therapies for patients with residual disease beyond T-DM1.

Adrienne G. Waks, MD, details her approach to treatment sequencing in metastatic HER2-positive disease and the potential role of T-DXd in the first line.

Adrienne G. Waks, MD, parses out recent and upcoming data in HER2+ breast cancer and discusses why abbreviated neoadjuvant regimens are not ready for primetime.

Sarah Sammons, MD, discusses the evolving treatment landscape for metastatic HER2-postive breast cancer.